4//SEC Filing
Furiex Pharmaceuticals, Inc. 4
Accession 0001437749-14-012512
CIK 0001484478operating
Filed
Jul 6, 8:00 PM ET
Accepted
Jul 7, 4:40 PM ET
Size
14.5 KB
Accession
0001437749-14-012512
Insider Transaction Report
Form 4
ESHELMAN FREDRIC N
Director
Transactions
- Disposition to Issuer
Stock Options (to buy)
2014-07-02−98,813→ 0 total(indirect: By LLC)Exercise: $13.16Exp: 2021-10-03→ Common Stock (98,813 underlying) - Disposition to Issuer
Common Stock
2014-07-02−2,673,522→ 0 total - Disposition to Issuer
Common Stock
2014-07-02−41,666→ 0 total(indirect: GRAT) - Disposition to Issuer
Stock Options (to buy)
2014-07-02−65,876→ 0 total(indirect: By LLC)Exercise: $9.11Exp: 2020-06-17→ Common Stock (65,876 underlying) - Disposition to Issuer
Common Stock
2014-07-02−132,689→ 0 total(indirect: By LLC) - Disposition to Issuer
Common Stock
2014-07-02−140→ 0 total(indirect: By Spouse)
Footnotes (3)
- [F1]Pursuant to the Agreement and Plan of Merger by and among Forest Laboratories, Inc., Royal Empress, Inc. and Furiex Pharmaceuticals, Inc. (the "Company") dated as of April 27, 2014 (the "Agreement"), each share of the Company's common stock was exchanged for $95.00 in cash, without interest, less any applicable withholding taxes ("Cash Consideration"), plus one contingent value right (a "CVR"), which represents the right to receive contingent payments of up to approximately $30.00 in cash in the aggregate, without interest, less any applicable withholding taxes, if specified milestones are achieved within agreed upon time periods.
- [F2]All options became 100% vested on June 11, 2014 in connection with the Agreement.
- [F3]Pursuant to the Agreement, each stock option of the Company was exchanged for (A) an amount in cash equal to the product of (1) the total number of shares of the Company's common stock subject to the option immediately prior to the effective time multiplied by (2) the excess, if any, of the per Cash Consideration over the exercise price per share of common stock under the option and (B) one CVR multiplied by the total number of shares of common stock subject to the option (assuming full vesting of the option) had the Reporting Person exercised such option in full immediately prior to the effective time of the merger.
Documents
Issuer
Furiex Pharmaceuticals, Inc.
CIK 0001484478
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001484478
Filing Metadata
- Form type
- 4
- Filed
- Jul 6, 8:00 PM ET
- Accepted
- Jul 7, 4:40 PM ET
- Size
- 14.5 KB